BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION AND THE LOCALIZATION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS

被引：0
|
作者：
Manzella, L. [1 ]
Massimino, M. [1 ]
Fallica, M. [1 ]
Consoli, M. L. [1 ]
Aloisi, A. [1 ]
Messina, A. [1 ]
Vigneri, P. [1 ]
机构：
[1] Univ Catania, Dept Biomed Sci, Sect Gen Pathol, Catania, Italy
来源：
HAEMATOLOGICA | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
C052
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [21] Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer
    Zamecnikova, Adriana
    EXPERT REVIEW OF HEMATOLOGY, 2010, 3 (01) : 45 - 56
  • [22] SYNTHESES AND PROPERTIES OF DRUGS INHIBITORS OF BCR-ABL TYROSINE KINASE, USED IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
    de Azevedo, Liviane D.
    Bastos, Monica M.
    de Oliveira, Andressa Paula
    Boechat, Nubia
    QUIMICA NOVA, 2017, 40 (07): : 791 - 809
  • [23] IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation
    Massimino, Michele
    Consoli, Maria Letizia
    Mesuraca, Maria
    Stagno, Fabio
    Tirro, Elena
    Stella, Stefania
    Pennisi, Maria Stella
    Romano, Chiara
    Buffa, Pietro
    Bond, Heather M.
    Morrone, Giovanni
    Sciacca, Laura
    Di Raimondo, Francesco
    Manzella, Livia
    Vigneri, Paolo
    CARCINOGENESIS, 2014, 35 (05) : 1132 - 1143
  • [24] Interaction of a novel signaling protein (AHI-1) with BCR-ABL modulates BCR-ABL transforming activity and imatinib response of chronic myeloid leukemia progenitor cells
    Zhao, Yuri
    Zhou, Leon
    Ringrose, Ashley
    Lin, Ann E. -J.
    Kennah, Erin
    Sheng, Guoqing
    Li, Xiao-Jiang
    Turhan, Ali
    Jiang, Xiaoyan
    BLOOD, 2007, 110 (11) : 144A - 144A
  • [25] AHI-1, a novel signaling protein, interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib sensitivity of primitive chronic myeloid leukemia cells
    Zhao, Y.
    Zhou, L.
    Ringrose, A.
    Lin, A. E.
    Turban, A. G.
    Jiang, X.
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (09) : 21 - 22
  • [26] Improved FRET Biosensor for the Measurement of BCR-ABL Activity in Chronic Myeloid Leukemia Cells
    Horiguchi, Mika
    Fujioka, Mari
    Kondo, Takeshi
    Fujioka, Yoichiro
    Li, Xinxin
    Horiuchi, Kosui
    Satoh, Aya O.
    Nepal, Prabha
    Nishide, Shinya
    Nanbo, Asuka
    Teshima, Takanori
    Ohba, Yusuke
    CELL STRUCTURE AND FUNCTION, 2017, 42 (01) : 15 - 26
  • [27] Role of interferon regulatory factor 5 in chronic myeloid leukemia
    Manzella, L.
    Massimino, M.
    Fallica, M.
    Consoli, M. L.
    Aloisi, A.
    Vigneri, P.
    Messina, A.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 : 66 - 66
  • [28] Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia
    Verma, Dushyant
    Fava, Carmen
    Kantarjian, Hagop
    Cortes, Jorge
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (04) : 256 - 257
  • [29] The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels
    Wang, Jiaqiao
    Hu, June
    Jin, Zhiliang
    Wan, Huihui
    LEUKEMIA RESEARCH, 2016, 47 : 32 - 40
  • [30] Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
    Etienne, Gabriel
    Dulucq, Stephanie
    Huguet, Francoise
    Schmitt, Anna
    Lascaux, Axelle
    Hayette, Sandrine
    Fort, Marie-Pierre
    Sujobert, Pierre
    Bijou, Fontanet
    Morisset, Stephane
    Tavitian, Suzanne
    Bidet, Audrey
    Turcq, Beatrice
    Robbesyn, Fanny
    Chollet, Claudine
    Belloc, Francis
    Durrieu, Francoise
    Mahon, Francois-Xavier
    Nicolini, Franck E.
    CANCER MEDICINE, 2019, 8 (11): : 5173 - 5182
12345